Research Topics
| Anthony V D'AmicoSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancerAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Cancer 95:275-80. 2002....- Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk diseaseAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
J Clin Oncol 22:3726-32. 2004..We investigated whether pretreatment factors predicted time to prostate cancer-specific mortality (PCSM) after conventional-dose and conformal radiation therapy (CRT)... - Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapyAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
J Urol 172:S42-6; discussion S46-7. 2004..A short posttreatment prostate specific antigen (PSA)-doubling time (DT) following radical prostatectomy or radiation therapy was evaluated as a surrogate end point for prostate cancer specific mortality (PCSM)... - Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancerAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
J Urol 173:1572-6. 2005..We determined whether prostate specific antigen (PSA) velocity can serve as surrogate end point for prostate cancer specific mortality (PCSM) in patients with nonmetastatic, hormone refractory prostate cancer... - Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortalityAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
Cancer 109:1290-5. 2007.... - Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trialAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Faber Cancer Institute, Boston, MA 02215, USA
Lancet Oncol 8:21-5. 2007..We aimed to assess the effect of 1 mg/day finasteride on serum PSA in men aged 40-60 years with male-pattern hair loss... - Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapyAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Mass 02215, USA
JAMA 294:440-7. 2005..Men with localized prostate cancer and a preoperative prostate-specific antigen (PSA) velocity greater than 2.0 ng/mL per year experience a 10-fold increase in prostate cancer-specific mortality despite surgery... - Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failureAnthony V D'Amico
Brigham and Women s Hospital, Department of Radiation Oncology, Dana Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 23:4975-9. 2005..We evaluated whether men at risk for significant versus clinically insignificant prostate-specific antigen (PSA) failure after radical prostatectomy could be identified using information available at diagnosis... - Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancerAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Urology 66:571-6. 2005.... - Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancerAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, 75 Francis Street, Boston, MA 02215, USA
J Urol 176:S11-5. 2006..We identified factors at diagnosis that are significantly associated with time to prostate cancer specific mortality following radical prostatectomy or external beam radiation therapy... - Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen levelAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
J Clin Oncol 24:4190-5. 2006.... - A prospective evaluation of rectal bleeding after dose-escalated three-dimensional conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilizationAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Urology 67:780-4. 2006.... - 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trialAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Mass 02215, USA
JAMA 292:821-7. 2004.... - Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapyMona V Sanghani
Department of Radiation Oncology, The Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA, USA
Urol Oncol 22:165-8. 2004.... - Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomyAnthony V D'Amico
Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, USA
N Engl J Med 351:125-35. 2004..We evaluated whether men at risk for death from prostate cancer after radical prostatectomy can be identified using information available at diagnosis... - Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen eraAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 95:281-6. 2002.... - Radiation and hormonal therapy for locally advanced and clinically localized prostate cancerAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Urology 60:32-7; discussion 37-8. 2002..Validation of this predictive factor by others is needed... - Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen eraAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 54:436-41. 2002..To evaluate the change in prostate-specific antigen (PSA) outcome after radical prostatectomy (RP) or external beam radiotherapy (EBRT), controlling for follow-up during the PSA era... - Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancerAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
J Clin Oncol 20:4567-73. 2002..Identifying pretreatment and posttreatment predictors of time to prostate cancer-specific death (PCSD) after external-beam radiation therapy (RT) was the subject of this study... - Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinomaAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, 75 Francis Street, L 2 Level, Boston, MA 02115, USA
Cancer 97:56-62. 2003.... - Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen eraAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
J Clin Oncol 21:2163-72. 2003..To determine whether pretreatment risk groups shown to predict time to prostate cancer-specific mortality (PCSM) after treatment at a single institution retained that ability in a multi-institutional setting... - Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctionsAnthony V D'Amico
Departments of Radiation Oncology and Medicine, Cardiovascular Division, Brigham and Women s Hospital and Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
J Clin Oncol 25:2420-5. 2007..We evaluated whether the timing of fatal myocardial infarction (MI) was influenced by the administration of androgen suppression therapy (AST)... - Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostateAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Cancer 109:2004-10. 2007.... - Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapyAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
J Natl Cancer Inst 95:1376-83. 2003..Therefore, we evaluated the hypothesis that a short post-treatment PSA doubling time (PSA-DT) after radiation therapy is a surrogate end point for prostate cancer-specific mortality by analyzing two multi-institutional databases... - Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen eraAnthony V D'Amico
Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02215, USA
J Urol 170:S42-6; discussion S46-7. 2003..Identifying pretreatment and posttreatment predictors of time to prostate cancer specific death (PCSD) following external beam radiation therapy (RT) is the subject of this study... - Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failureAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
J Natl Cancer Inst 96:509-15. 2004.... - Predictors of mortality after prostate-specific antigen failureAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA, USA
Int J Radiat Oncol Biol Phys 65:656-60. 2006..We identified factors associated with the length of survival after prostate-specific antigen (PSA) failure... - Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortalityHenry K Tsai
Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA 02215, USA
J Natl Cancer Inst 99:1516-24. 2007..We investigated whether androgen deprivation therapy (ADT) use is associated with an increased risk of death from cardiovascular causes in patients treated for localized prostate cancer... 
Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrenceJennifer Y Wo
Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
J Clin Oncol 27:6000-5. 2009....- Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapyAkash Nanda
Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 76:1439-44. 2010..a luteinizing hormone-releasing hormone (LHRH) agonist alone affects the risk of prostate cancer-specific mortality (PCSM) in men with localized but high-risk disease treated with radiotherapy... - Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrencePaul L Nguyen
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Cancer 116:610-5. 2010..Therefore, our ability to determine who would benefit from salvage hormonotherapy (HT) would be enhanced if an individual's risk of nonprostate-cancer-specific mortality were known... - Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of deathAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
Int J Radiat Oncol Biol Phys 75:10-5. 2009..To assess whether the risk of death is associated with the time to testosterone recovery (TTR) after radiotherapy (RT) and hormonal therapy (HT) for prostate cancer (PCa)... - Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostateKaren M Winkfield
Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, USA
Int J Radiat Oncol Biol Phys 81:e345-50. 2011.... - Population-based determinants of radical prostatectomy surgical margin positivityStephen B Williams
Division of Urologic Surgery, Center for Surgery and Public Health, Dana Farber Cancer Institute, Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
BJU Int 107:1734-40. 2011..Prognosis (cohort)... - Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk groupPaul L Nguyen
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Int J Radiat Oncol Biol Phys 77:1046-52. 2010..RT alone in men with unfavorable risk localized prostate cancer (PCa), but it is unknown if this benefit applies to all risk subgroups and, in particular, the intermediate-risk group... - Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of deathToni K Choueiri
Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer 116:1887-92. 2010..BCR) as a time-dependent covariate (t) after radical prostatectomy (RP) for prostate cancer was associated with the risk of death and whether salvage therapy with radiotherapy (RT) and/or hormonal therapy (HT) can lessen this risk.. - Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancerPaul L Nguyen
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
BJU Int 110:201-5. 2012.... - Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II studyPaul L Nguyen
Harvard Radiation Oncology Program, Boston, MA 02115, USA
Brachytherapy 8:345-52. 2009..Patient-reported quality of life (QOL) after salvage brachytherapy for radiorecurrent prostate cancer has not been well-characterized prospectively... - Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivationPaul L Nguyen
Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Cancer 117:406-13. 2011.... - Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failureAlexandra J Stewart
Brigham and Women s Hospital, Dana Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 23:6556-60. 2005..2 ng/mL was significantly associated with prostate cancer-specific mortality (PCSM)... - Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockadeNeil E Martin
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA Department of Statistics, University of Connecticut, Storrs, CT Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
BJU Int 110:1252-6. 2012..In this study, we found that among men treated with 6 months of combined androgen blockade and radiation therapy, higher biopsy Gleason grade was associated with a shorter time to testosterone normalization... - Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancerAyal A Aizer
Harvard Radiation Oncology Program, Massachusetts General Hospital, Department of Radiation Oncology, 100 Blossom St, Cox 3, Boston, MA 02114, USA
J Clin Oncol 30:3071-6. 2012..The purpose of this study was to determine whether consultation at a multidisciplinary clinic is associated with selection of active surveillance in patients with low-risk prostate cancer... - The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selectionDaniel A Wattson
Harvard Radiation Oncology Program, Department of Radiation Oncology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 82:e773-9. 2012.... - Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarctionPaul L Nguyen
Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Int J Radiat Oncol Biol Phys 82:1411-6. 2012.... - Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendationsPaul L Nguyen
Harvard Radiation Oncology Program, Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 76:337-41. 2010..The U.S. Preventive Services Task Force has recommended against screening men over 75 for prostate cancer. We examined whether older healthy men could benefit from aggressive prostate cancer treatment... - Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancerKaren E Hoffman
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
Cancer 116:2590-5. 2010..The authors of this report compared the use of brachytherapy alone with combined brachytherapy, external-beam radiation to the prostate and seminal vesicles, and androgen-suppression therapy (CMT) in this population... - Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate sizePaul L Nguyen
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 79:1318-22. 2011..Brachytherapy for prostate cancer can be technically challenging in men with small prostates (≤20 cc), but it is unknown whether their outcomes are different than those of men with larger prostates... - Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapyAkash Nanda
Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 77:147-52. 2010.... - The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statementArthur K Cheung
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
Brachytherapy 9:145-50. 2010..We investigated the patterns of care in the community in this patient population before and after the reporting of the ABS guideline... - Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilizationRosemonde Woel
Joint Center for Radiation Therapy, Brigham and Women s Hospital and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 62:392-6. 2005..A modified intrarectal balloon (Medrad) was used for prostate gland localization and immobilization... - Salvage radiation in men after prostate-specific antigen failure and the risk of deathShane E Cotter
Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, Massachusetts, USA
Cancer 117:3925-32. 2011..Whether such a benefit exits in men with a protracted PSA rise in DT (≥ 6 months) is unclear and was examined in the current study... - Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapyPing Zhou
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 23:6992-8. 2005..We evaluated predictors of prostate cancer-specific mortality (PCSM) after prostate-specific antigen (PSA) failure after radical prostatectomy (RP) or radiation therapy (RT)... - Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapyMichele Albert
Department of Radiation Oncology, Brigham and Women s Hospital, 75 Francis Street, L 2 Level, Boston, MA 02115, USA
Cancer 98:949-54. 2003..This study was designed to estimate the rates of late genitourinary (GU) and rectal toxicity after magnetic resonance image (MRI)-guided prostate brachytherapy exclusively or in conjunction with external beam radiation therapy (EBRT)... - Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapyAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
Cancer 110:1723-8. 2007..The authors evaluated whether the duration of androgen suppression (AS) after the completion of hormone therapy (HT) was associated with the risk of prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM)... - Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancerHenry K Tsai
Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, USA
Cancer 107:2597-603. 2006..The authors estimated PCSM after radiation therapy with short-course androgen suppression therapy (RT+AST) or radical prostatectomy (RP) in men with clinically localized, intermediate-risk to high-risk prostate cancer... - Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trialAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
JAMA 299:289-95. 2008..Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST)... - Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapyAnthony V D'Amico
Department of Radiation, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
J Clin Oncol 26:2979-83. 2008..We determined the risk of recurrence in men enrolled on a randomized trial for prostate cancer who were treated with radiation therapy (RT) alone or in conjunction with combined or less than combined androgen suppression therapy (AST)... - Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapyRonald C Chen
Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
Int J Radiat Oncol Biol Phys 75:36-9. 2009..We examined whether maximum androgen blockade (MAB) is associated with a decreased recurrence risk vs. single-agent androgen suppression (monotherapy) for men undergoing brachytherapy (BT) for localized prostate cancer... - Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancerJosephine Kang
Harvard Radiation Oncology Program, Brigham and Women s Hospital, Department of Radiation Oncology, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 82:e463-7. 2012..In this study we evaluated whether DM Type 1, 2, or both are associated with high-grade PCa after adjusting for known predictors of high-grade disease... - Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarctionAkash Nanda
Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, 75 Francis St, ASB1 L2, Boston, MA 02115, USA
JAMA 302:866-73. 2009..However, it is unknown which comorbid conditions eliminate this survival benefit... - Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factorsPaul L Nguyen
Harvard Radiation Oncology Program, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 73:659-64. 2009..To determine whether the number of unfavorable risk factors could be used to predict the risk of prostate cancer-specific mortality (PCSM) among men with intermediate- to high-risk prostate cancer... - Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factorsAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
Cancer 110:56-61. 2007..Estimates of prostate cancer-specific mortality (PCSM) were determined after radical prostatectomy (RP) or radiation therapy (RT) in men with >or=1 high-risk factors... - Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary eraPaul L Nguyen
Harvard Radiation Oncology Program, Boston, MA, USA
Int J Radiat Oncol Biol Phys 74:104-9. 2009..We examined the accuracy of this formula in contemporary patients... - Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trialsAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
Lancet Oncol 13:189-95. 2012..Thus, we assessed whether prostate-specific antigen (PSA) values can act as an early surrogate for prostate cancer-specific mortality (PCSM)... - Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapyHenry K Tsai
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
Urol Oncol 23:230-7. 2005..To investigate the impact of 2 months of neoadjuvant and 2 months of concurrent hormonal therapy on the acute gastrointestinal (GI) toxicities associated with 3-dimensional conformal radiation therapy (3D-CRT) for prostate adenocarcinoma... - Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancerJason A Efstathiou
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 109:1493-8. 2007..Whether BMI is associated with time to PSA failure was investigated in men treated with androgen suppression therapy (AST) and radiation therapy (RT) for clinically localized prostate cancer... - Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancerClair Beard
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 66:403-7. 2006..To identify an association between perineural invasion (PNI) and cancer-specific survival in patients with prostate cancer after standard-dose external beam radiation therapy (RT)... - Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literaturePaul L Nguyen
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer 110:1417-28. 2007.... - Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapyAmy M Dosoretz
Department of Radiation Oncology, Harvard Radiation Oncology Program, Boston, Massachusetts 02115, USA
Cancer 116:837-42. 2010..Therefore, the objective of the current study was to examine the effect of NHT on the risk of ACM in men with prostate cancer who receive with brachytherapy... - Defining the rectal dose constraint for permanent radioactive seed implantation of the prostateMichele Albert
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
Urol Oncol 26:147-52. 2008..This study was performed to define the rectal dose constraint that would predict late rectal bleeding requiring argon plasma coagulation (APC) following prostate brachy mono-therapy... - Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortalityChristine S Chung
Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
Urology 71:136-40. 2008..2 ng/mL or less) after 8 months of androgen suppression therapy (AST)... - Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancerAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
Cancer 113:3290-7. 2008..The authors estimated and characterized mortality after androgen suppression therapy (AST) use in men with newly diagnosed localized and recurrent prostate cancer... - Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for managementPaul L Nguyen
Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer 113:3146-52. 2008.... - p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682)Anthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
Urology 71:933-7. 2008..It has been hypothesized that abnormal p53 protein expression is associated with a worse prognosis after radiation (RT) and androgen suppression therapy (AST). This hypothesis was prospectively tested... - Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experienceStanley L Liauw
Department of Radiation Oncology, University of Texas Southwestern Medical Center at Dallas, 75390-9110, USA
Urology 61:1204-10. 2003..CONCLUSIONS: Salvage RT is moderately effective in treating patients with locally persistent or recurrent prostate adenocarcinoma. Seminal vesicle invasion and lymphovascular invasion predicted for unsuccessful treatment...